您的位置: 首页 > 农业专利 > 详情页

NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
专利权人:
DOV PHARMACEUTICAL; INC.
发明人:
SKOLNICK, PHIL,CHEN, ZHENGMING,BASILE, ANTHONY,EPSTEIN, JOSEPH W
申请号:
NZ59283606
公开号:
NZ592836A
申请日:
2006.07.25
申请国别(地区):
NZ
年份:
2013
代理人:
摘要:
592836 Disclosed are derivatives of 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane and 1-(naphthalen-1-yl)-3-aza-bicyclo[3.1.0]hexane as represented by the general formulae (II) and (III), and enantiomers and pharmaceutically acceptable salts thereof, wherein: R1 and R2 are independently selected from hydrogen, unsubstituted alkyl, alkenyl and alkynyl, and substituted alkyl, alkenyl and alkynyl R3 is selected from hydrogen, alkyl, alkoxycarbonyl, alkanoyl, cycloalkyl, cycloalkanoyl, aryl, heteroaryl, saturated heterocyclic, alkenyl, alkynyl, and substituted alkyl, alkenyl and alkynyl and R4 and R5 are independently hydrogen or 1-4 substituents independently selected from halogen, alkyl, alkenyl, alkynyl, haloalkyl, cyano, hydroxy, cycloalkyl, alkoxy, alkoxyalkyl, carboxyalkyl, alkanoyl, haloalkoxy, nitro, amino, alkylamino, and dialkylamino and wherein the remaining substituents are as defined herein. Representative compounds include 1-(2-methoxynaphthalen-6-yl)-3-methyl-3-aza-bicyclo[3.1.0]hexane, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, (1S,5R)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, (1R,5S)-3-methyl-1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane, (1S,5R)-3-methyl-1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane, 3-isopropyl-1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane, 3-ethyl-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, 1-(naphthalen-1-yl)-3-aza-bicyclo[3.1.0]hexane, (1R,5S)-1-(naphthalen-1-yl)-3-azabicyclo[3.1.0]hexane, (1R,5S)-3-methyl-1-(naphthalen-1-yl)-3-aza-bicyclo[3.1.0]hexane, 1-(1-fluoronaphthalen-4-yl)-3-aza-bicyclo[3.1.0]hexane and 1-(1-methylnaphthalen-4-yl)-3-aza-bicyclo[3.1.0]hexane. Further disclosed is a pharmaceutical composition comprising an effective amount of a compound as defined above and a pharmaceutical acceptable carrier or vehicle therefor, for treating or preventing a central nervous system (CNS) disorder such as depression, an anxiety disorder, or an attention deficit disorder.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充